Bone health after age 60 sits at the intersection of several converging clinical realities: accelerating bone loss that began at the menopause or with age-related sex hormone decline has now accumulated over a decade or more; falls risk — the proximate cause of most hip and wrist fractures — begins to rise from the early 60s due to muscle loss, balance impairment, and polypharmacy; and the fracture consequences of osteoporosis become more severe, with hip fractures carrying a 20–30% excess one-year mortality rate in older adults. At the same time, the evidence base for intervention is strongest in this age group — bisphosphonates, denosumab, and other pharmacological agents have been extensively studied in postmenopausal women aged 60–80 and reduce fracture risk by 30–50%. This guide covers what changes in bone after 60, how fracture risk is assessed and managed in this decade, and the specific clinical priorities that distinguish bone health at 60 from bone health at 50.
How Bone Changes From 60 Onwards
By the mid-60s, the acute phase of postmenopausal bone loss — the 2–3% per year at the spine characteristic of the early postmenopausal period — has typically slowed to approximately 1% per year. However, this ongoing loss, compounded over the 10–15 years since menopause, means that women who entered their 60s with borderline T-scores in the osteopenia range may now be approaching or already within the osteoporosis range. For women who delayed addressing bone health through their 50s, the 60s is often the decade in which the consequences — a fragility fracture, a DEXA revealing osteoporosis — first become apparent.
In men, bone loss accelerates somewhat from the 60s onwards as testosterone and oestradiol levels continue to decline, and age-related impairment of intestinal calcium absorption and vitamin D activation compounds the effect. Hip fracture rates in men begin to rise from the late 60s and represent a significant clinical burden by the 70s. Our guide to osteoporosis in men covers male-specific bone health in detail.
Cortical vs trabecular bone: Age-related bone loss in the 60s and 70s falls predominantly on cortical bone (the dense outer shell of long bones), whereas the acute postmenopausal loss in the 50s falls predominantly on trabecular bone (the spongy inner structure of the spine and femoral neck). This explains why hip fracture rates — which depend primarily on cortical bone strength at the proximal femur — rise most steeply from the 60s onward, whereas spinal compression fractures (trabecular bone) are more common in the early postmenopausal years. Both types of fracture increase with age, but their relative prevalence reflects this difference in the pattern of bone loss.
Falls: The Proximate Cause of Most Fractures
Osteoporosis increases fracture risk, but the majority of hip and wrist fractures in older adults require a fall — they do not arise from everyday activities. Falls prevention is therefore a critical and often underweighted component of bone health management after 60. Several age-related changes increase falls risk from the 60s onward:
Sarcopenia — the progressive loss of muscle mass and strength from the 30s onward — becomes clinically significant in the 60s and 70s, with reduced lower-limb strength impairing the rapid muscle responses needed to prevent a stumble from becoming a fall. Our guide to protein and bone strength covers the muscle-bone interdependency and the protein requirements that support muscle preservation in older adults.
Balance and gait impairment — reduced proprioception, vestibular function, and visual acuity from the 60s onward increase instability. Balance training (tai chi, yoga, specific balance exercises) has a well-established evidence base for falls reduction in older adults — a Cochrane review of tai chi in older adults found a 29% reduction in falls rate in regular practitioners.
Polypharmacy — older adults on multiple medications, particularly sedating drugs (benzodiazepines, antihistamines, opioids), antihypertensives, and antidepressants (especially SSRIs), have substantially elevated falls risk. Medication review by a GP or pharmacist is a standard component of falls prevention assessment and should be considered when an older adult falls or is assessed for fracture risk.
Home environment hazards — loose rugs, poor lighting, lack of grab rails in the bathroom, and cluttered walkways contribute to falls in the home (where the majority of older adult falls occur). Occupational therapy assessment of home fall hazards is available through NHS referral for those at high falls risk.
Pharmacological Treatment After 60
By the 60s, a substantial proportion of women — and a smaller but growing proportion of men — will have FRAX-estimated 10-year fracture probabilities above the NICE intervention threshold, qualifying for pharmacological bone treatment. Understanding the main treatment options is increasingly relevant for adults in this age group:
Bisphosphonates (alendronate, risedronate, zoledronate) are the most widely used first-line agents for osteoporosis. They work by inhibiting osteoclast activity, reducing bone resorption and slowing bone loss. Alendronate (70 mg weekly) and risedronate (35 mg weekly) are taken orally; zoledronate is given as an annual intravenous infusion and is particularly useful for those who cannot tolerate oral bisphosphonates (oesophageal irritation is a common problem with oral agents). Bisphosphonates reduce vertebral fracture risk by 40–50% and hip fracture risk by 25–40% in postmenopausal osteoporosis trials. They are generally taken for 3–5 years, after which a treatment holiday is considered; bisphosphonates accumulate in bone and continue providing some protection during the holiday period.
Denosumab (Prolia) is a monoclonal antibody that inhibits RANKL, the signalling molecule that stimulates osteoclast maturation. Given as a 60 mg subcutaneous injection every 6 months, it produces larger BMD gains than bisphosphonates at both the spine and hip. Denosumab is often used when bisphosphonates are not tolerated or not appropriate (e.g., impaired renal function, in which oral bisphosphonates are contraindicated). An important clinical note: denosumab must not be stopped abruptly — discontinuation causes a rebound increase in bone turnover with risk of multiple vertebral fractures, and transition to a bisphosphonate is required when stopping.
Teriparatide (Forsteo) is a recombinant fragment of PTH that stimulates osteoblasts, building new bone rather than just preventing its resorption. It is reserved for severe osteoporosis (T-score below −3.5, or multiple vertebral fractures) and is given as a daily subcutaneous injection for 18–24 months, followed by an antiresorptive agent to preserve the BMD gains.
All pharmacological treatments are prescribed by a GP or specialist after FRAX and DEXA assessment establish fracture risk above the treatment threshold. Adherence to oral bisphosphonates is a practical challenge — oesophageal side effects and the requirement to remain upright for 30–60 minutes after taking the tablet lead some patients to stop taking them prematurely; the intravenous option (zoledronate once yearly) achieves better adherence in these cases. Our guide to osteoporosis in women after menopause covers the prescribing pathways and treatment choices in more detail.
Fracture Liaison Services
Fracture Liaison Services (FLS) are NHS specialist teams that systematically identify, assess, and manage patients who have sustained a fragility fracture — typically a fracture from a standing height fall or minor injury in a person over 50. They bridge a well-documented gap: population studies consistently show that fewer than 20% of patients who sustain a fragility fracture receive osteoporosis assessment and treatment, despite a prior fragility fracture being one of the strongest predictors of future fracture.
If you or a family member sustains a fracture after a minor fall — particularly a wrist, vertebral, hip, or shoulder fracture in someone over 50 — and are not referred to an FLS or offered bone density assessment, it is appropriate to ask the GP or orthopaedic team whether a referral is indicated. NICE guidance specifically recommends assessment and treatment for osteoporosis following a fragility fracture in adults over 50.
Nutrition After 60
Nutritional needs for bone health intensify further in the 60s, with declining absorption efficiency, reduced appetite, and lower overall food intake in some older adults combining to increase the risk of deficiency:
Calcium: Adults over 60 continue to require 700–1,200 mg/day, but calcium absorption efficiency declines further with age and with vitamin D deficiency. Achieving this from diet alone requires deliberate attention — dairy products remain the most bioavailable source (approximately 300 mg per 200 ml serving of milk), but fortified plant milks, canned fish with bones, tofu set with calcium sulphate, and calcium-rich vegetables (kale, pak choi, broccoli) all contribute. Our guide to calcium and bone health covers sources and absorption factors.
Vitamin D: Year-round supplementation of 800–1,000 IU/day is appropriate for most adults over 65, as skin synthesis efficiency declines substantially with age and many older adults have limited sun exposure. The UK Chief Medical Officers recommend 10 µg (400 IU) daily year-round for all adults over 65; higher doses (800–1,000 IU) are supported by meta-analyses of fracture prevention trials in this age group. Our guide to vitamin D and bone health covers evidence for supplementation in older adults, including the combined effect of vitamin D plus calcium on hip fracture risk.
Protein: Maintaining protein intake at 1.0–1.2 g/kg/day is particularly important in the 60s to support muscle mass against progressive sarcopenia. Frail older adults are at risk of protein-energy malnutrition — reduced appetite, social isolation, and difficulty cooking can each reduce food intake below what is needed to maintain muscle. Protein distribution across meals (rather than one large protein-rich meal) optimises muscle protein synthesis in older adults. Our guide to protein and bone strength covers the muscle-bone connection and fracture recovery protein needs.
Magnesium and vitamin K2 remain important cofactors for bone quality. Magnesium supports PTH regulation and vitamin D activation; inadequate magnesium impairs both. Vitamin K2 (MK-7) activates osteocalcin and MGP — proteins that direct calcium into bone and prevent vascular calcification. Our guides to magnesium and bone health and vitamin K and bone health cover these in detail.
Exercise After 60
Exercise remains the most effective non-pharmacological intervention for both bone density and falls prevention after 60, though the emphasis shifts compared to the 50s:
Balance and coordination training becomes as important as — or more important than — weight-bearing aerobic exercise for fracture prevention in the 60s and 70s, because falls prevention has a large and direct effect on fracture rates independently of bone density. Tai chi, yoga, and specific balance exercise programmes reduce falls rates in older adults by 20–35% in randomised trials. The Royal Osteoporosis Society recommends balance training as a dedicated component of bone health exercise in older adults, not merely an add-on.
Resistance training continues to provide bone stimulus and is critical for sarcopenia prevention. In adults over 60, beginning or maintaining a progressive resistance programme (targeting legs, hips, back, and shoulders) 2–3 times per week produces ongoing BMD maintenance benefit and reduces falls risk through improved lower-limb strength. Starting from low resistance and progressing gradually is appropriate for older adults new to resistance training — a physiotherapist or certified exercise specialist with older-adult experience can guide appropriate starting intensity.
Weight-bearing aerobic exercise (brisk walking, dancing, low-impact aerobics) remains appropriate for most adults in their 60s and contributes ongoing bone stimulus, though high-impact activities (jogging, jumping) should be approached with caution in those with established osteoporosis or prior fracture, where the fracture risk from a misstep may outweigh the bone benefit. Walking remains beneficial and appropriate for virtually all adults over 60 regardless of bone status.
Frequently Asked Questions
Is it too late to improve bone health at 60?
No — it is never too late to take action that reduces fracture risk, and the 60s is precisely the age group in which pharmacological treatment (bisphosphonates, denosumab) provides the strongest and best-evidenced fracture risk reduction. Clinical trials of bisphosphonates have been conducted predominantly in postmenopausal women aged 65–80 — the evidence that fracture risk is reduced by 30–50% comes from this age group. Resistance training and balance training also reduce falls risk in people in their 60s and 70s. The goal at 60 is not to undo the bone loss that occurred in the 50s — that is not achievable through lifestyle measures — but to slow further loss, maintain muscle and balance to prevent falls, and, where pharmacological treatment is indicated, to substantially reduce the probability of fracture.
When should bisphosphonates be started?
Bisphosphonates are initiated when FRAX-estimated 10-year fracture probability is above the age-appropriate NICE intervention threshold, or when T-score falls below the osteoporosis threshold (−2.5) with additional risk factors. A GP or specialist will calculate FRAX and, if a DEXA has been done, incorporate the BMD result. Many women in their 60s who have not previously been assessed for fracture risk will qualify for bisphosphonate treatment when first assessed — the combination of age, years of postmenopausal bone loss, and other clinical risk factors often pushes FRAX above threshold even without a very low BMD. A prior fragility fracture — even a wrist fracture from a minor fall — in a woman over 50 is itself a strong indication for treatment. The FLS pathway, GP referral following DEXA, or GP-initiated FRAX assessment are the routes to a treatment decision.
How dangerous are hip fractures after 60?
Hip fractures are the most clinically serious consequence of osteoporosis. The 30-day mortality rate following hip fracture in older adults is approximately 5–10%, and the 1-year mortality is 20–30% — largely due to complications of prolonged immobility (pneumonia, pulmonary embolism, pressure sores) and the general frailty that often predates the fracture. Of those who survive a hip fracture, only 50–60% regain their pre-fracture walking ability, and a significant proportion require long-term residential care that would not have been needed without the fracture. These figures reflect the clinical imperative for prevention — identifying and treating osteoporosis before a hip fracture occurs avoids an event that is often life-altering. The 30–40% hip fracture risk reduction from bisphosphonate treatment in at-risk populations is clinically significant precisely because the consequences of the prevented event are so severe.
What is a Fracture Liaison Service?
A Fracture Liaison Service (FLS) is an NHS specialist team that identifies patients who have had a fragility fracture — a fracture from a minor fall or low-energy impact — and ensures they receive appropriate osteoporosis assessment and treatment. Despite guidelines recommending assessment after any fragility fracture, studies consistently show that fewer than 1 in 5 patients who sustain such a fracture receive osteoporosis evaluation and treatment without an FLS in place. If you or a family member sustains a wrist, vertebral, hip, or shoulder fracture from a minor fall and is over 50, asking the treating team whether you should be referred to the FLS or have bone density testing is entirely appropriate. Not every hospital has an equally active FLS — in some settings this assessment needs to be requested rather than automatically provided.
How can I reduce my falls risk at 60?
The evidence-based approach to falls prevention at 60 and beyond involves four complementary components. First, exercise — specifically balance training (tai chi, yoga, balance exercises) and resistance training to maintain lower-limb strength, both of which reduce falls rates by 20–35% in trials. Second, medication review — sedating medications, certain antihypertensives, and SSRIs increase falls risk; a GP or pharmacist review of all medications is warranted if falls are occurring. Third, vision and hearing assessment — poor vision and vestibular impairment contribute to falls and are often under-assessed; up-to-date glasses and hearing aid use reduce falls risk. Fourth, home safety assessment — removing loose rugs, improving lighting, installing grab rails in the bathroom, and clearing clutter from walkways reduces falls in the home environment, where most older adult falls occur.
Do I still need calcium and vitamin D supplements at 60 if I eat dairy?
Calcium can generally be obtained from diet if dairy intake is adequate and consistent — three servings of dairy per day (a glass of milk, a pot of yogurt, a portion of cheese) provides approximately 700–900 mg of calcium, meeting the daily requirement. However, vitamin D cannot be reliably obtained from diet or sun exposure in older adults. Vitamin D-rich foods (oily fish, eggs, fortified products) provide at most 200–300 IU/day — well below the 400–800 IU supplementation recommended for adults over 65. Sun exposure, while theoretically a source, is limited by skin synthesis efficiency (which halves between age 20 and 70), sun avoidance behaviour, and winter months. Year-round vitamin D supplementation (400–800 IU/day) is recommended for all adults over 65 regardless of dietary intake. If dietary calcium intake is uncertain or below target, supplementation of 500–600 mg/day (not higher) can bridge the gap.
What should I expect from a DEXA scan referral after 60?
A DEXA (dual-energy X-ray absorptiometry) scan is a quick (10–20 minute), low-radiation scan that measures bone mineral density at the spine (lumbar vertebrae L1–L4) and hip (femoral neck and total hip). Results are reported as T-scores — the number of standard deviations above or below the average peak bone mass of a young adult. T-score between −1.0 and −2.5 indicates osteopenia (below-normal but not osteoporosis); T-score below −2.5 indicates osteoporosis. The scan result is combined with the FRAX clinical risk factors to produce an overall fracture probability estimate, which determines whether pharmacological treatment is recommended. You may also receive a Z-score (comparison to age-matched peers) and a TBS (trabecular bone score) at some centres. Results are typically discussed with your GP, who will arrange follow-up if treatment is indicated.
Summary
Bone health after age 60 involves managing the accumulated bone loss of the postmenopausal decade, addressing the rising falls risk that makes fracture consequences more severe, and utilising the well-evidenced pharmacological and lifestyle interventions that are most impactful in this age group. Proactive FRAX assessment and DEXA scanning for those above threshold, year-round vitamin D supplementation (800–1,000 IU/day), adequate calcium and protein, and a combined programme of resistance training and balance exercise are the foundation. For those with elevated fracture risk, bisphosphonates or denosumab provide 30–50% reductions in fracture risk that lifestyle measures alone cannot match. Falls prevention — through exercise, medication review, vision assessment, and home safety — is an equally important and often underweighted element of fracture prevention. Our companion guide to bone health after age 50 covers the earlier decade, and our guide to fracture risk: what adults should know covers FRAX and DEXA assessment in detail.
Medical disclaimer: This article is for general educational purposes and does not constitute medical advice. Consult a qualified healthcare professional for personalised bone health assessment and management.
References:
NHS. Osteoporosis. nhs.uk. 2023.
NICE CG146. Osteoporosis: assessing the risk of fragility fracture. NICE. 2023.
Royal Osteoporosis Society. Strong, Steady and Straight: expert consensus on physical activity and exercise for osteoporosis. theros.org.uk. 2019.
Gillespie LD et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012.
Compston JE et al. Osteoporosis. The Lancet. 2017.
I was diagnosed with osteoporosis at 64 after my first DEXA scan — T-score of −2.8 at the spine and −2.4 at the hip. I had never broken a bone but my FRAX score put my 10-year major fracture probability at 24%, which was above the treatment threshold. My GP prescribed alendronate 70 mg weekly. I found it difficult at first — the requirement to take it first thing in the morning on an empty stomach and then stay upright for 30 minutes before eating was disruptive to my morning routine, and in the first few weeks I had some oesophageal discomfort. My GP switched me to risedronate and the side effects resolved. I have now been on risedronate for four years and my last DEXA (at year 3) showed my spine T-score had improved to −2.3. My GP explained this is typical — bisphosphonates don’t produce large BMD gains but they do slow or reverse loss and the fracture risk reduction is real even with modest BMD changes. The article’s explanation of bisphosphonate mechanism, typical side effects of oral agents, and the option of intravenous zoledronate for those who cannot tolerate oral treatment is information I wish I had been given when I started.
Janet, your experience illustrates two important clinical points. First, the side effect profile of oral bisphosphonates — particularly oesophageal irritation with alendronate — is a known and manageable issue, and switching within the class (to risedronate, which has a different formulation and somewhat lower GI irritation profile) or to intravenous zoledronate is a well-established option rather than simply stopping treatment. Second, the T-score improvement from −2.8 to −2.3 over three years is a meaningful response — you are correct that fracture risk reduction from bisphosphonates precedes and exceeds what the BMD change alone would predict, through an effect on bone quality (mineralisation, microdamage repair) in addition to BMD. Your current course of maintaining risedronate, with reassessment at five years for potential treatment holiday consideration, is the appropriate pathway. Barbara, your mother’s case reflects a pattern that is unfortunately common: a prior fragility fracture at 68 (the wrist fracture) that was not investigated for osteoporosis, and multiple unidentified risk factors, meaning the hip fracture at 72 was the first event to trigger assessment. The FLS referral and denosumab initiation at 10 months post-fracture is the right management, though it comes after the most severe event. Your family’s experience is an important reminder of why proactive FRAX assessment and FLS self-referral or asking for referral after any fragility fracture over 50 matters so much — the wrist fracture was a warning sign that could have prompted assessment and treatment four years before the hip fracture occurred.
My mother had a hip fracture at 72 — she fell on a wet kitchen floor and fractured her right neck of femur. She had surgery the next day and spent three weeks in hospital and then six weeks in a rehabilitation unit. She is now home at 10 months post-fracture, walking with a walking frame, but she has not regained the independence she had before. Before the fracture she lived alone, drove, and was fully mobile. She now needs daily care assistant visits and will not be returning to driving. She was referred to the Fracture Liaison Service from the fracture clinic, who identified that she had never been assessed for osteoporosis despite multiple risk factors (she smoked for 30 years, stopped at 65, had a low BMI, and had a prior wrist fracture at 68 that was never investigated). She was started on denosumab injections. The article’s description of hip fracture outcomes — the 20–30% one-year excess mortality and the fact that only 50–60% of survivors regain previous walking ability — is accurate and something the family wishes we had been warned about before it happened.